We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$46M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$398K
▲ +138.9% YoY
Op. Margin
—
ROIC
-31.67%
▲ +30.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$51M
▼ -32.0% YoY
Op. Cash Flow (TTM)
-$51M
▼ -30.6% YoY
Net Debt
-$101M
Net Cash Position
Cash & Equiv.
$107M
Continue Research